Press Releases
The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors Excerpt from the Press Release: NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first patient…
Read More
SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…
Read More
Adam Miller, MD, to Serve as Lead Investigator for the First Randomized, Placebo Controlled Trial of CCR5 Antagonists and Statins for Chronic COVID Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and…
Read More
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Nov. 18, 2021– Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology. (instead of CNSide detected CSF tumor cells…
Read More
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators Excerpt from the Press Release:…
Read More
Primary endpoint data expected in Q1 2022 SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the…
Read More
Aiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patch
Excerpt from the Press Release: An East Bay company formulated a Covid-19 vaccine candidate to load onto a patch of 2,000 microneedles, one of several efforts globally to make it easier to take drugs and vaccines to combat the pandemic. Zosano Pharma Corp. (NASDAQ: ZSAN) of Fremont did not disclose the name of the vaccine,…
Read More
Excerpt from the Press Release: SAN DIEGO, Nov. 18, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from two scientific posters for its Phase 2 clinical studies of VAL-083, the Company’s lead compound for the treatment of glioblastoma multiforme (GBM). …
Read More
Study will investigate how a broad range of exposures affect brain and child development BOSTON, Nov. 17, 2021 /PRNewswire/ — Boston Children’s Hospital has been awarded two five-year grants by the National Institutes of Health (NIH) to co-lead the HEALthy Brain and Child Development (HBCD) study, an ambitious, comprehensive national study of brain development from birth through early…
Read More
Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disorders Excerpt from the Press Release: MADRID, Spain and CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code:…
Read More